Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02593162 · ClinicalTrials.gov registry record · Phase 2
A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection
A Phase 2 study, sponsored by Trek Therapeutics, PBC.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT02593162: Completed Phase 2 study, sponsored by Trek Therapeutics, PBC.
NCT02593162 is a Phase 2 study that has completed, run by Trek Therapeutics, PBC. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02593162, a Phase 2 study, has completed, sponsored by Trek Therapeutics, PBC.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Phase 2a study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir and TD-6450 in combination with Ribavirin for a 12-week treatment duration in treatment-naïve participants with genotype 4 hepatitis C virus (HCV) infection.
Interventions
- DRUG Ribavirin
- DRUG TD-6450
- DRUG Faldaprevir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
What the finished NCT02593162 record still lists
NCT02593162 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 3 interventions - of which Ribavirin is the first listed.
NCT02593162 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02593162 about?
NCT02593162 is a clinical study titled "A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection". Phase 2a study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir and TD-6450 in combination with Ribavirin for a 12-week treatment duration in treatment-naïve participants with genotype 4 hepatitis C virus (HCV) infection.
What is the current status of trial NCT02593162?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2015-10. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02593162?
The interventions under investigation include: Ribavirin (DRUG), TD-6450 (DRUG), Faldaprevir (DRUG).
Who is sponsoring clinical trial NCT02593162?
This trial is sponsored by Trek Therapeutics, PBC, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02593162's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia